Introducing OsStic™ Technology,
The First True Bone BioAdhesive
The Challenges of Periarticular Fractures
Periarticular fractures have postoperative complication rates of up to 37%, with an average failure rate of 10–20% for patients with lower extremity fractures[1]
Periarticular fractures represent some of the most complex and demanding challenges in orthopedic trauma care. Fragment size, shape, or poor bone quality make reduction and stabilization difficult—leading to articular surface collapse, joint incongruity, and long-term functional impairment.[2]
Current fixation methods fail when periarticular fragments are too small or do not allow for adequate screw purchase due to bone loss. No material to date offers immediate adhesion to bone with sufficient mechanical stability through the bone healing process.
A Breakthrough Bone BioAdhesive
Now, periarticular fracture management is entering a new era. OsStic™ is a bioadhesive technology, developed by Biomimetic Innovations in Ireland, designed to transform fracture management and bone repair. By bonding at the nanoscale, OsStic™ enhances bone integrity to recreate joint surfaces into a composite, load-sharing construct. OsStic™ technology offers structural support for periarticular fractures, adhesive properties for fracture reduction and provisional fixation, and enables bone remodeling while maintaining stability.[3]
Powered by Phosphoserine: Nature’s Adhesive Blueprint
OsStic™ leverages phosphoserine—a key component of the bone regeneration process—combined with α-TCP and calcium silicate. This creates an adhesive matrix with 40x stronger bonding than traditional calcium phosphate cement.[4]
Benefits Of OsStic™ Technology
OsStic™ technology addresses the critical limitations of current provisional fixation techniques in periarticular fractures, especially in cases of severe comminution and articular impaction.
OsStic™ Technology is currently in development and has received Breakthrough Device Designation from the FDA in 2023.
References
- Kalmet PHS, Andriessen MT, Maduro CV, et al. The economic burden of the postoperative management in surgically treated trauma patients with peri- and/or intra-articular fractures of the lower extremities: A prospective multicenter cohort study. Injury. 2021;52(11):3286–3294. doi:10.1016/j.injury.2021.08.049
- Court-Brown CM, Duckworth AD. Fracture epidemiology and the role of orthopedic innovation. Bone Joint J. 2017;99-B(7):851–857.
- Bojan AJ, Stadelmann VA, Wu D, et al. A new bone adhesive candidate—does it work in human bone? An ex-vivo preclinical evaluation in fresh human osteoporotic femoral head bone. Injury. 2022;53(10):1858–1866.
https://doi.org/10.1016/j.injury.2022.04.007
- Data on file. Preclinical mechanical testing data.
https://doi.org/10.1016/j.injury.2022.04.007
OsStic™ Technology is currently under development and has received Breakthrough Device Designation from the FDA. The product is not cleared or released for commercial use.
The contents of PBC Biomed or Biomimetic Innovation Limited (BMI) material are protected by worldwide copyright and trademark laws. Any rights not expressly granted herein are reserved. Reproduction, transfer, distribution or storage of part or all of the contents in any form without the prior written permission of PBC Biomed or Biomimetic Innovation Limited is prohibited.
MKT.19.01 251002
